The simultaneous targeting of EGFR and the nonreceptor tyrosine kinase PYK2/FAK synergistically inhibited the proliferation of TNBC cells in vitro and suppressed tumor growth in a mouse xenograft model, proposing a promising and efficient therapeutic strategy for basal-like TNBC. Here, PTK2B is linked to neoplasm.